Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome

[1]  P. Schoenfeld,et al.  Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. , 2016, Gastroenterology.

[2]  M. Schmulson,et al.  Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico☆ , 2016 .

[3]  M. Schmulson,et al.  Experiencia clínica con el uso de los anticuerpos anti-CdtB y anti-vinculina en pacientes con diarrea en México , 2016 .

[4]  C. Manichanh,et al.  Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome , 2015, Scientific Reports.

[5]  M. El-Salhy.  Recent developments in the pathophysiology of irritable bowel syndrome. , 2015, World journal of gastroenterology.

[6]  G. Barlow,et al.  Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects , 2015, PloS one.

[7]  G. Barlow,et al.  Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model , 2015, Digestive Diseases and Sciences.

[8]  P. Moayyedi,et al.  American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation , 2014, The American Journal of Gastroenterology.

[9]  N. Talley,et al.  Report from the multinational irritable bowel syndrome initiative 2012. , 2013, Gastroenterology.

[10]  G. Barlow,et al.  Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome , 2012, Journal of neurogastroenterology and motility.

[11]  Ning Wang,et al.  Vinculin-dependent Cadherin mechanosensing regulates efficient epithelial barrier formation , 2012, Biology Open.

[12]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  R. Gunsalus,et al.  Methanobrevibacter smithii Is the Predominant Methanogen in Patients with Constipation-Predominant IBS and Methane on Breath , 2012, Digestive Diseases and Sciences.

[14]  M. Simrén,et al.  Short‐term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification , 2012, Alimentary pharmacology & therapeutics.

[15]  Matthew E. Berginski,et al.  The Vinculin C-terminal Hairpin Mediates F-actin Bundle Formation, Focal Adhesion, and Cell Mechanical Properties* , 2011, The Journal of Biological Chemistry.

[16]  G. Locke,et al.  Epidemiology of IBS. , 2011, Gastroenterology clinics of North America.

[17]  J. C. López-Alvarenga,et al.  Prevalencia y caracterización de los subtipos de SII según los criterios de Roma III, en un estudio clínico, multicéntrico. Reporte del grupo mexicano de estudio para el SII , 2010 .

[18]  E. Soffer,et al.  ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. , 2010, World journal of gastroenterology.

[19]  B. Spiegel,et al.  Is Irritable Bowel Syndrome a Diagnosis of Exclusion?: A Survey of Primary Care Providers, Gastroenterologists, and IBS Experts , 2010, The American Journal of Gastroenterology.

[20]  J. Remes-Troche,et al.  [Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group]. , 2010, Revista de gastroenterologia de Mexico.

[21]  W. Chey,et al.  An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome , 2008, The American Journal of Gastroenterology.

[22]  D. Bayles,et al.  The Contribution of Cytolethal Distending Toxin to Bacterial Pathogenesis , 2006, Critical reviews in microbiology.

[23]  F. Mearin,et al.  Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. , 2005, Gastroenterology.

[24]  L. Chang,et al.  Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact , 2005, Alimentary pharmacology & therapeutics.

[25]  Hyojin Park,et al.  Post‐infectious irritable bowel syndrome in patients with Shigella infection , 2005, Journal of gastroenterology and hepatology.

[26]  K. DeMali.  Vinculin--a dynamic regulator of cell adhesion. , 2004, Trends in biochemical sciences.

[27]  N. Dalton,et al.  Animal Model Heterozygous Inactivation of the Vinculin Gene Predisposes to Stress-Induced Cardiomyopathy , 2004 .

[28]  H. Dupont,et al.  Post-Diarrhea Chronic Intestinal Symptoms and Irritable Bowel Syndrome in North American Travelers to Mexico , 2004, The American Journal of Gastroenterology.

[29]  R. Spiller.  Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective. , 2003 .

[30]  J. Barton,et al.  Is Irritable Bowel Syndrome More Common in Patients Presenting With Bacterial Gastroenteritis? A Community-Based, Case-Control Study , 2003, American Journal of Gastroenterology.

[31]  R. Spiller.  Postinfectious irritable bowel syndrome. , 2003, Gastroenterology.

[32]  R. Spiller,et al.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study , 2002, Gut.

[33]  C. Pickett,et al.  The cytolethal distending toxin family. , 1999, Trends in microbiology.

[34]  T. King.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea. , 1996, Clinical nutrition.

[35]  N. Read,et al.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea , 1996, The Lancet.